PR Newswire·Aug 31, 2026, 9:03 AM ET

Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

Wolf Haldenstein Adler Freeman & Herz LLP filed a securities class action lawsuit in the US District Court for the Southern District of California on behalf of investors who acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) common stock.
The class period covers shares purchased or acquired pursuant to the IPO documents issued on February 13, 2025, or between February 13, 2025, & May 14, 2026.
The lead plaintiff deadline is set for October 13, 2026.
The complaint alleges defendants failed to disclose that the drug candidate ARD-101 was less safe than represented, overstating its clinical, regulatory, & commercial prospects.
The alleged truth emerged on February 27, 2026, when Aardvark voluntarily paused its Phase 3 HERO trial due to reversible cardiac observations found in a healthy volunteer study.
Following the announcement, Aardvark's stock price fell $7.02 per share, or 56.2%, closing at $5.47 on March 2, 2026.
The law firm invites affected investors to contact them at no cost or obligation via phone or email for further investigation assistance.